^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    IMM0306

    i
    Other names: IMM0306
    Company:
    ImmuneOnco Biopharma
    Drug class:
    CD20 inhibitor, CD47 inhibitor
    Related drugs:
    5ms
    High Level of IL-16 Secreted By Non-GCB DLBCL Facilitates Tumor Growth Though the Tumor-Promoting and Immunosuppressive Tumor Microenvironment (ASH 2023)
    The dynamic change of serum IL-16 levels accurately predicted the treatment response in patients with DLBCL who received R-CHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone) or anti-CD19 Chimeric Antigen Receptor (CAR) T cells. In conclusion, this study provides insight into the expression and role of IL-16 in DLBCL. IL-16 is proposed to be highly expressed in ABC-DLBCL, and serum IL-16 indicate the tumor burden, treatment response, and clinical prognosis of DLBCL patients. IL-16 may be a key driver of the TME of DLBCL, which can confer growth advantage to the ABC-DLBCL.
    IL6 (Interleukin 6) • IL10 (Interleukin 10) • CASP3 (Caspase 3) • IL16 (Interleukin 16)
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone • IMM0306
    1year
    Preliminary results from a phase I/II study of IMM0306, a CD47 and CD20 bispecific monoclonal antibody-trap, in patients with relapsed or refractory CD20-positive B-cell non-Hodgkin's lymphoma. (ASCO 2023)
    IMM0306 was well-tolerated and with a robust preliminary anti-tumor activity especially in pts with R/R FL and MZL. The phase I/II study is ongoing. Clinical trial information: CTR20192612.
    Clinical • P1/2 data
    |
    CD20 (Membrane Spanning 4-Domains A1) • SIRPA (Signal Regulatory Protein Alpha)
    |
    CD20 positive
    |
    IMM0306
    1year
    Study of IMM0306 in Patients With Relapsed or Refractory CD20-positive B-cell Non-Hodgkin's Lymphoma (clinicaltrials.gov)
    P1/2, N=154, Recruiting, ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
    New P1/2 trial
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    IMM0306
    over1year
    Preliminary Safety and Efficacy Evaluation of IMM0306, a CD47 and CD20 Bispecific Monoclonal Antibody-Trap (mAb-Trap), from an Ongoing Phase I Dose-Escalation Study in Patients with Relapsed or Refractory B-Cell Non- Hodgkin's Lymphoma (R/R B-NHL) (ASH 2022)
    These data indicate that IMM0306 is well-tolerated at the dose levels evaluated. and preliminary anti-tumor efficacy result observed support continuous development of IMM0306 in patients with R/R B-NHL. The phase 1/2 is ongoing.
    Clinical • P1 data
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    IMM0306